Drug Trial Radar · NCT00606502
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Last checked: Nov 20, 2026Latest source record: Mar 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
201
Actual
Start
Jan 2008
Primary completion
Jun 24, 2010
Study completion Jun 24, 2010
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Conditions
- Non-small Cell Lung Cancer
Interventions
PralatrexateDrug
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications. Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
ErlotinibDrug
150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
Vitamin B12Dietary supplement
1 mg intramuscular injection Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.
Folic AcidDietary supplement
1-1.25 mg orally Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) of Patients Receiving Pralatrexate vs. ErlotinibTime frame: Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.
Locations
47 sites in 6 countries. Site status is shown where the registry gives one.
Comprehensive Blood and Cancer Center
Bakersfield, California
Sharp Memorial Hospital
San Diego, California
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida
Northwestern University Feinberg School of Medicine
Chicago, Illinois
University of Kansas Cancer Center
Westwood, Kansas
Donald Berdeaux
Great Falls, Montana
Summit Medical Group
Berkeley Heights, New Jersey
Hematology and Oncology Associates South Jersey
Mount Holly, New Jersey
New York Oncology Hematology-Oncology Associates, P.C.
Latham, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
New Bern Cancer Care
New Bern, North Carolina
Signal Point Clinical Research Center
Middletown, Ohio
Baptist Regional Cancer Center
Knoxville, Tennessee
Cancer Therapy and Research Center
San Antonio, Texas
Providence Everett Medical Center
Everett, Washington
Hospital Britanico
Capital Federal, Argentina
Centro Oncologico Rosario
Rosario, Argentina
CAIPO (Centero Para la Atencion Integral del Paciente Oncologico)
San Miguel de Tucumán, Argentina
ISIS Clinica Especializada
Santa Fe, Argentina
Policlinica Privada - Instituto de Medicina Nuclear
Bahía Blanca, Buenos Aires, Argentina
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Cuidad de Buenos Aires, Argentina
Biocancer S.A.
Belo Horizonte, Brazil
Instituto do Cancer - Arnaldo Vieira de Carvalho
São Paulo, Brazil
Associação Hospital de Caridade de Ijuí
Ijuí, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Clinionco - Clínica de Oncologia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital do Câncer de Barretos
Barretos, São Paulo, Brazil
Masarykuv onkologicky ustav
Brno, Czechia
Palacký University Medical School and Teaching Hospital
Olomouc, Czechia
Vitkovicka nemocnice, a. s.
Ostrava, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Nemocnice Na Homolce
Prague, Czechia
Fakultni nemocnice na Bulovce
Prague, Czechia
Matrai Allami Gyogyintezet
Mátraháza, Hungary
Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza
Tatabánya, Hungary
National Koranyi TBC and Pulmonology Institute
Budapest, Pest County, Hungary
Jósa András Teaching Hospital
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
Vas County Markusovszky Hospital
Szombathely, Vas County, Hungary
Zala County Hospital
Zalaegerszeg, Zala County, Hungary
Dharmashila Cancer Hospital & Research Centre
New Delhi, India
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.